Table 1.
Anthropometric, biochemical, clinical, and cardiac parameters at cardiac magnetic resonance (CMR) in patients with acromegaly and controls
| ACRO (n = 20) | CTRL (n = 17) | p value | |
|---|---|---|---|
| Anthropometric parameters | |||
| Sex (M/F) | 13/7 | 8/9 | 0.457 |
| Age, years | 50.0 ± 12.4 | 57.5 ± 11.1 | 0.063 |
| BMI kg/m2 | 27.6 (20.7–36.4) | 26.5 (21.3–32.3) | 0.456 |
| Waist circumference, cm | 101.5 (72.0-111.0) | 100 (85.0-108.4) | 0.503 |
| Systolic BP, mmHg | 120 (90–140) | 120 (105–140) | 0.477 |
| Diastolic BP, mmHg | 70 (58–90) | 80 (60–85) | 0.826 |
| Heart rate, beats/min | 64.5 ± 10.5 | 69.5 ± 9.1 | 0.127 |
| Biochemical parameters | |||
| Fasting plasma glucose, mg/dL | 97 (63–124) | 99 (77–143) | 0.887 |
| HbA1c, % | 5.7 ± 0.66 | 5.8 ± 0.45 | 0.757 |
| Fasting plasma insulin, µUI/mL | 5.1 (1.5–16.0) | 9.7 (3.4–26.8) | 0.015 |
| HOMA-i | 1.05 (0.23–3.48) | 2.08 (0.77–7.53) | 0.025 |
| Triglycerides, mg/dL | 95.0 (42.0-231.0) | 112.0 (38.0-216.8) | 0.334 |
| Total cholesterol, mg/dL | 188.7 ± 34.3 | 198.4 ± 40.1 | 0.444 |
| HDL cholesterol, mg/dL | 53.5 ± 12.5 | 60.0 ± 11.0 | 0.328 |
| LDL cholesterol, mg/dL | 114.5 (63.0-181.0) | 105.0 (50.0-179.4) | 0.574 |
| Clinical parameters | |||
| OSAS, n (%) | 2 (10.0%) | 0 (0.0%) | 0.081 |
| Hypertension, n (%) | 10 (50.0%) | 7 (41.1%) | 0.591 |
| Obesity, n (%) | 6 (30%) | 4 (23.3%) | 0.659 |
| Diabetes mellitus, n (%) | 3 (15.0%) | 5 (29.4%) | 0.289 |
| IFG, n (%) | 6 (30.0%) | 3 (17.6%) | 0.383 |
| IGT, n (%) | 1 (5.0%) | 1 (5.8%) | 0.906 |
| Dyslipidemia, n (%) | 9 (45.0%) | 6 (35.2%) | 0.549 |
| Anti-hypertensive drugs | 9 (45.0%) | 7 (41.1%) | 0.815 |
| Anti-diabetic drugs | 3 (15.0%) | 4 (23.5%) | 0.509 |
| Lipid-lowering drugs | 4 (20%) | 4 (23.5%) | 0.795 |
| Cardiac parameters at CMR | |||
| LV-EDVi (ml/m2) | 79.6 ± 13.8 | 61.7 ± 11.5 | < 0.001 |
| LV-ESVi (ml/m2) | 33.9 ± 7.8 | 23.8 ± 7.0 | < 0.001 |
| LV-SVi (ml/m2) | 45.7 ± 9.2 | 37.9 ± 7.1 | 0.007 |
| LV-EF (%) | 57.5 ± 6.1 | 61.6 ± 6.7 | 0.069 |
| LVMi (g/m2) | 57.1 ± 14.2 | 43.5 ± 8.5 | 0.001 |
| LVH (yes/no)/ (%) | 1/20 (5.0%) | 0/17 (0.0%) | 0.350 |
| Concentricity index (g/mL) | 0.72 ± 0.15 | 0.74 ± 0.18 | 0.782 |
| IVS thickness (mm) | 11.5 (7.0–17.0) | 10.0 (7.0-13.4) | 0.128 |
| RV-EDVi (ml/m2) | 89.7 ± 19.7 | 63.4 ± 9.7 | < 0.001 |
| RV-ESVi (ml/m2) | 44.8 ± 13.0 | 25.8 ± 6.4 | < 0.001 |
| RV-SVi(ml/m2) | 44.9 ± 9.3 | 37.6 ± 7.6 | 0.021 |
| RV-EF (%) | 50.6 ± 6.0 | 59.3 ± 7.7 | 0.001 |
| T1-preMean (ms) | 995.5 ± 31.1 | 997.1 ± 18.7 | 0.889 |
| T1-postMean (ms) | 444.3 ± 51.3 | 406.9 ± 50.0 | 0.038 |
| ECV (%) | 26.0 ± 2.8 | 25.9 ± 2.1 | 0.979 |
Anthropometric clinical, biochemical, and morpho-structural and functional cardiac parameters in patients with acromegaly and matched controls at the time of enrolment.
M = male, F = female, BMI = body mass index, BP = blood pressure, OSAS = obstructive sleep apnea syndrome, IFG = impaired fasting glucose, IGT = impaired glucose tolerance
LV-EDVi = left ventricle end-diastolic volume indexed, LV-ESVi = left ventricle end-systolic volume indexed, LV-SVi = left ventricle stroke volume indexed, LV-EF = left ventricle ejection fraction, LVMi = left ventricle mass indexed, IVS = interventricular septum, RV-EDVi = right ventricle end-diastolic volume indexed, RV-ESVi = right ventricle end-systolic volume indexed, RV-SVi = right ventricle stroke volume indexed, RV-EF = right ventricle ejection fraction, ECV = extracellular volume